Targeting Gαq/11 may be an efficient therapeutic strategy against uveal melanoma

Announcing a new article publication from Acta Pharmaceutica Sinica B. Constitutively activated G proteins caused by specific mutations mediate the development of multiple malignancies. The mutated Gαq/11 are perceived as oncogenic drivers in the vast majority ofuveal melanoma(UM) cases, making directly targeting Gαq/11 to be a promising strategy for combating UM.

In this article, the authors report the optimization of imidazopiperazine derivatives as Gαq/11 inhibitors and identified GQ262 with improved Gαq/11 inhibitory activity and drug-like properties. GQ262 efficiently blocked UM cell proliferation and migration in vitro. Analysis of the apoptosis-related proteins, extracellular signal-regulated kinase (ERK), and yes-associated protein (YAP) demonstrated that GQ262 distinctly induced UM cells apoptosis and disrupted the downstream effectors by targeting Gαq/11 directly. Significantly, GQ262 showed outstanding antitumor efficacy in vivo with good safety at the testing dose.

These findings along with the favorable pharmacokinetics of GQ262 suggest that directly targeting Gαq/11 may be an efficient strategy against uveal melanoma.

Journal reference:

Ge, Y., et al. (2022) Discovery of small molecule Gαq/11 protein inhibitors against uveal melanoma. Acta Pharmaceutica Sinica B.


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
You might also like...
Study reveals a new potential treatment approach for glioblastoma